久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Gen-Probe 
Gen-Probe公司（美國分子生物學檢測方法創始公司之一，是FDA指定的為美國血庫作檢測的公司），位于美國圣地亞哥，是一個在開發、制造和商業化基于它的專利基因探針技術的診斷產品的公認的世界領導公司。

　　在用基因探針試驗檢測微生物的領域中，公司已經取得41個FDA許可，包括那些可致性傳播疾病、肺結核、咽喉炎、肺炎和真菌感染等。

　　Gen-Probe現在正在開發病毒核酸試驗用于篩查血源中的HIV-1、丙肝和乙肝病毒，并同此領域的世界上領導公司如bioMérieux,Chiron, 和Bayer保持合作關系。

       

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fastest-growing segments of the in vitro diagnostics industry.

Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), tuberculosis, strep throat, pneumonia and fungal infections. Gen-Probe's key clinical diagnostics products include the APTIMA COMBO 2? and PACE? assays, which are used to detect the common STDs Chlamydia and gonorrhea.

In blood screening, Gen-Probe developed and manufactures the PROCLEIX? assay, which is used to detect HIV-1 and the hepatitis C virus (HCV) in donated human blood; the PROCLEIX ULTRIO? assay, which detects the hepatitis B virus in addition to HIV-1 and HCV; and the PROCLEIX WNV (West Nile virus) assay. Gen-Probe's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics, Inc.

Gen-Probe also has a robust development pipeline. For example, the Company is developing NATs to detect prostate cancer, drug-resistant hospital infections, and human papillomavirus, which causes cervical cancer. In addition, Gen-Probe is working with General Electric and Millipore to develop NATs that detect microorganisms that commonly contaminate industrial processes.

Several of Gen-Probe's current and future molecular diagnostic tests can be performed on the Company's TIGRIS? instrument, the only fully automated, high-throughput NAT system for diagnostics and blood screening.

Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.